scPharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview

Scpharmaceuticals

12/05/2025 21:29

scPharmaceuticals Inc SCPH.OQ SCPH.O is expected to show a rise in quarterly revenue when it reports  results on May 14 for the period ending March 31 2025

The Burlington Massachusetts-based  company is expected to report a 90.6% increase in revenue to $11.628 million from $6.1 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for scPharmaceuticals Inc is for a loss of 30 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for scPharmaceuticals Inc is $12.50​, above​ its last closing price of $2.44. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.44
-0.38
-0.35
Beat
7.5
Sep. 30 2024
-0.29
-0.30
-0.75
Missed
-153
Jun. 30 2024
-0.42
-0.41
-0.44
Missed
-6.3​
Mar. 31 2024
-0.44
-0.44
-0.36
Beat
17.6
​​Dec. 31 2023
-0.52
-0.42
-0.35
Beat
16.4
Sep. 30 2023
-0.37
-0.36
-0.41
Missed
-12.4​
Jun. 30 2023
-0.37
-0.37
-0.36
Beat
3.3
Mar. 31 2023
-0.39
-0.36
-0.30
Beat
17.8

This summary was machine generated May 12 at 20:29 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)